Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1210834-55-1

Post Buying Request

1210834-55-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • N-α-(9-Fluorenylmethoxycarbonyl)-N-α-methyl-D-cyclohexylalanine;N-α-(9-Fluorenylmethoxycarbonyl)-N-α-methyl-β-cyclohexyl-D-alanine

    Cas No: 1210834-55-1

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

1210834-55-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1210834-55-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,0,8,3 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1210834-55:
(9*1)+(8*2)+(7*1)+(6*0)+(5*8)+(4*3)+(3*4)+(2*5)+(1*5)=111
111 % 10 = 1
So 1210834-55-1 is a valid CAS Registry Number.

1210834-55-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (R)-2-((((9H-Fluoren-9-Yl)Methoxy)Carbonyl)(Methyl)Amino)-3-Cyclohexylpropanoic Acid

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1210834-55-1 SDS

1210834-55-1Downstream Products

1210834-55-1Relevant articles and documents

Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators

Fernandez, Kleinberg X.,Fischer, Conrad,Gheblawi, Mahmoud,Gottschalk, Samantha,Iturrioz, Xavier,Oudit, Gavin Y.,Vederas, John C.,Vu, Jennie,Wang, Wang,Llorens-Cortés, Catherine

, p. 1402 - 1413 (2021)

High blood pressure and consequential cardiovascular diseases are among the top causes of death worldwide. The apelinergic (APJ) system has emerged as a promising target for the treatment of cardiovascular issues, especially prevention of ischemia reperfusion (IR) injury after a heart attack or stroke. However, rapid degradation of the endogenous apelin peptides in vivo limits their use as therapeutic agents. Here, we study the effects of simple homologue substitutions, i.e. incorporation of non-canonical amino acids l-cyclohexylalanine (l-Cha) and l-homoarginine (l-hArg), on the proteolytic stability of pyr-1-apelin-13 and apelin-17 analogues. The modified 13-mers display up to 40 times longer plasma half-life than native apelin-13 and in preliminary in vivo assay show moderate blood pressure-lowering effects. The corresponding apelin-17 analogues show pronounced blood pressure-lowering effects and up to a 340-fold increase in plasma half-life compared to the native apelin-17 isoforms, suggesting their potential use in the design of metabolically stable apelin analogues to prevent IR injury. This journal is

Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists

Quartara,Fabbri,Ricci,Patacchini,Pestellini,Maggi,Pavone,Giachetti,Arcamone

, p. 3630 - 3638 (2007/10/02)

A series of cyclic pseudopeptides of the formula cyclo(LeuΨ[CH2NH]Xaa- Gln-Trp-Phe-βAla), where Xaa represents the residue of an α-amino acid, has been synthesized in order to establish the role of the Xaa side chain for tachykinin NK-2 recepto

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1210834-55-1